Tagged with novartis

Czech Republic One of the very first former-communist European states to attain a successful economic transition, the Czech Republic today puts across a compelling argument for being regarded as one of the regional leaders in pharmaceuticals, healthcare and life sciences.   In the Czech Republic we have the right balance between sophisticated…

Mexico Alexis Serlin, country president of Novartis Mexico and president of CANIFARMA, the industry chamber that brings together multinational and local drug manufacturers, explains how the pharmaceutical industry in Mexico aims to be recognized as a strategic sector by both the Ministries of Health and Economy. He highlights Novartis Mexico’s leadership in…

Novartis Dr Ann Aerts, head of the Novartis Foundation, discusses the role the Novartis Foundation plays within low and middle- income countries across the world and how integrating digital health solutions can strengthen health systems and contribute to global health.   We at the Novartis Foundation can leverage the expertise of…

Pharma Daniel Breitenstein, VP and GM of GSK Switzerland, discusses the benefits of GSK’s three-part transaction with Novartis; the importance of respiratory diseases and vaccines for future success; and how the company has changed its business model by no longer paying for physicians to speak on their behalf, setting in process…

Novartis Novartis Czech Republic’s Heidrun Irschik explains the potentially game-changing ramifications of Big Data on the Czech pharmaceutical and healthcare industries.   The opportunities offered by big data are present and we need to tap into this immense potential Heidrun Irschik, Novartis Big data: a technological phenomenon with potential commensurate to…

Pharma Professor Dr. Susan M. Gasser of the Friedrich Miescher Institute for Biomedical Research describes FMI’s fundamental connection between academia and industry in Switzerland, the effects of the foundation’s research, notably on Novartis, and future projects in the making. Could you begin by introducing both yourself and your institute to our…

Czech Republic There is frequent dialogue between the pharmaceutical industry, relevant regulatory authorities, and government stakeholders in the Czech Republic, but this dialogue is often strained. However, more frequent and constructive interaction between the myriad actors involved in Czech pharma and healthcare is helping push the industry to new heights.    Jan Žaloudík,…

Pharma The following chart shows the top pharma companies in Hungary ranked by sales value. Global giant Novartis leads the way with USD 240 million of sales, followed by domestic champion Egis with USD 150 million.  Click here to read more articles and interviews from Hungary

Pharma Manlio Florenzano discusses Sandoz’s engagement in Italy and the role of generics firms in contributing to a more affordable and sustainable Italian healthcare system. Can you please start by introducing Sandoz’s historic engagement with the Italian market? Sandoz began marketing in Italy back in 2000. My own background, meanwhile, was…

Pharma Novartis Italy’s Georg Schroeckenfuchs discusses the impact of the company’s global restructuring on the Italian affiliate, the significance of local manufacturing, new products, and how the Novartis has managed to become a market leader in Italy. A lot has been happening with Novartis globally lately: with big changes to the…

Pharma Francesco Carugi, Managing Director at Grifols Italy, discusses the company’s presence in the plasma, plasma products and plasma diagnostics segments, the impact of the liberalization of the Italian plasma market on their growth and business model and his commitment to driving change management to develop the affiliate’s future success. Grifols is…

France PharmaBoardroom spoke to Fabrice Chouraqui, President of Novartis Latin America and Canada at the Financial Times LatAm Healthcare & Life Sciences Summit in September 2015. He emphasizes the criticality of access to innovation for patients in one of the world’s fastest-growing regions. You were appointed President of Novartis Latin America…